Sybleu Inc. Stock

Equities

SYBE

US87114K1051

Pharmaceuticals

Delayed OTC Markets 03:59:37 2024-05-22 pm EDT 5-day change 1st Jan Change
0.0185 USD -25.25% Intraday chart for Sybleu Inc. -.--% -51.19%
Sales 2022 0.01 Sales 2023 0.01 Capitalization 3.02M
Net income 2022 - Net income 2023 - EV / Sales 2022 * -
Net Debt 2022 73.15K Net Debt 2023 474K EV / Sales 2023 298,725,376 x
P/E ratio 2022 *
-
P/E ratio 2023
-16.6 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 92.39%
More Fundamentals * Assessed data
Dynamic Chart
1 day-25.25%
1 month-57.27%
3 months-80.53%
6 months-40.32%
Current year-51.19%
More quotes
1 month
0.02
Extreme 0.0176
0.04
Current year
0.01
Extreme 0.011
0.15
1 year
0.01
Extreme 0.011
0.29
3 years
0.01
Extreme 0.011
0.29
5 years
0.01
Extreme 0.011
0.29
10 years
0.01
Extreme 0.011
0.29
More quotes
SYBLEU Inc. is engaged in the acquisition, licensing and development of medical and veterinary applications. The Company is focused on developing therapies for human and animal health, medical devices, and clinical diagnostics. The Company is also developing drugs for treating cancer in companion animals and examining the role of artificial intelligence and machine learning in clinical diagnostics. It is also involved in the development of disposable medical devices. It has completed Phase I and or Phase II clinical trials after which the Company would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials.
More about the company